Single uptake measurement for absorbed dose planning for radioiodine treatment of hyperthyroidism

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 3, 2003, Pages 473-479

  Jönsson, Helene ^a,b   Mattsson, Sören ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Swedish Radiation Protection Authority   (Sweden)

Author keywords

Hyperthyroidism; Iodine 131; Radioiodine therapy; Uptake

Indexed keywords

RADIOACTIVE IODINE;

ADOLESCENT; ADULT; AGE; AGED; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOSIMETRY; DRUG HALF LIFE; DRUG UPTAKE; GOITER; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RADIATION DOSE; RADIOISOTOPE THERAPY; SEX; THYROID ADENOMA;

EID: 0042743867     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803322285233     Document Type: Conference Paper

References (17)

1. Shapiro B. Optimization of radioiodine therapy of thyrotoxicosis: What have we learned after 50 years? J Nucl Med 1993;34:1638-1640.
2. Holm L-E, Hall P, Wiklund K, Lundell G, Berg G, Bjelkengren G, Cederquist E, Ericsson U-B, Hallquist A, Larsson L-G, Lidberg M, Lindberg S, Tennvall J, Wicklund H, Bojce Jr. JD Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst 1991; 83:1072-1077.
3. Isselt J, de Klerk J, Koppeschaar H, van Rijk P. Iodine-131 uptake and turnover rate vary over short intervals in Graves' disease. Nucl Med Com 2000;21:609-616.
4. Nordyke R, Gilbert F. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease. J Nucl Med 1991;32:411-416.
5. Ratcliffe G, Fogelman I, Maisey M. The evaluation of radioiodine therapy for thyroid patients using a fixed-dose regime. Br J Radiol 1986;59:1105-1107.
6. Jarlov A, Hegedus L, Kristensen L, Nygaard B, Hansen J. Is calculation of the dose in radioiodine therapy of hyperthyroidism worthwhile? Clin End 1995;45:325-329.
7. de Bruin T, Croon C, de Klerk J, van Isselt J. Standardized radioiodine therapy in Graves' disease: The persistent effect of thyroid weight and radioiodine uptake on outcome. J Intern Med 1994;236:507-513.
8. Clerc J, Izembart M, Dagousset F, Heshmati J, Chevalier A, Léger A, Barritault L. Influence of dose selection on absorbed dose in radioiodine treatment of diffuse toxic goiters in patients receiving or not receiving carbimazole. J Nucl Med 1993;34:387-393.
9. Bajnok L, Mezosi E, Nagy E, Szabo J, Sztojka I, Varga J, Galuska L, Leovey A. Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: Is more than seven-thousand rad target dose necessary? Thyroid 1999;9:865-869.
10. Bockisch A, Jamitzky T, Derwanz R, Biersack HJ. Optimized dose planning of radioiodine therapy of benign thyroidal diseases. J Nucl Med 1993;34:1632-1638.
11. IAEA. The calibration and standardization of thyroid radioiodine uptake measurements. Int J Appl Radiat Isotopes 1966;17:531-549.
12. ICRU. Phantoms and computational models in therapy, diagnosis and protection. ICRU Report 48, p 98.
13. Marinelli LD, Quimby EH, Hine GJ. Dosage determination with radioactive isotopes, practical considerations in therapy and protection. Am J Roentgenol 1948;2:260-281.
14. Haenscheid H, Lassmann, M, Boerner W. Aktivitaets-bestimmung vor Radiojodtherapie der Schilddruese-ein Vorschlag zur Minimierung von Aufwand und Fehler. Nuklearmedizin, 1993;32:A 128.
15. Hayes A, Akre C, Gorman C. Iodine-131 treatment of Graves' disease using modified iodine-131 uptake measurement in therapy dose calculation. J Nucl Med 1990; 31:519-522.
16. Kok S, Smit J, De Craen A, Goslings B, Van Eck-Smit B, Romjin J. Clinical outcome after standardized versus dosimetric radioiodine treatment of hyperthyroidism: An equivalence study. Nucl Med Com 2000;21:1071-1078.
17. Berg G, Michanek A, Holmberg E, Fink M. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements. J Nucl Med 1996;37:228-232.